Brief: Karolinska Development Portfolio Co's Eprenetapopt Reaches Primary Efficacy Endpoint In Combination Therapy Of Acute Myeloid Leukemia

Kdventures AB

17/06/2021 09:28

June 17 (Reuters) - Karolinska Development AB  KDEV.ST :
    * KAROLINSKA DEVELOPMENT’S PORTFOLIO COMPANY APREA
THERAPEUTICS
LEAD CANDIDATE DRUG EPRENETAPOPT REACHES PRIMARY EFFICACY
ENDPOINT IN COMBINATION THERAPY OF ACUTE MYELOID LEUKEMIA
    * RESULTS SHOW THAT PRIMARY EFFICACY ENDPOINT OF COMPLETE
REMISSION WAS REACHED IN 37% OF PATIENTS
    * DRUG CANDIDATE IS CURRENTLY UNDERGOING CLINICAL STUDIES AS
A
POTENTIAL TREATMENT FOR HEMATOLOGICAL MALIGNANCIES AND SOLID
TUMORS
    * APREA THERAPEUTICS WILL DISCUSS DATASET WITH U.S FOOD AND
DRUG
AGENCY (FDA) IN SECOND HALF OF 2021

Source text for Eikon:  ID:nGNE2CphBB 
Further company coverage:  KDEV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))